Back to top

Analyst Blog


Pall Corporation
(PLL - Analyst Report) has renewed a five-year $500 million revolving credit facility which was due to mature in June 2011. The interest rate on withdrawals from the credit line has been fixed on the lower side given the low interest-rate scenario and ample availability of credit.
 
Pall has recently refinanced its outstanding 6% senior notes due in 2012 aggregating to $280 million. The proceeds of these senior notes will be due in 2020.
 
Pall enjoys above-average financial returns and reasonable growth prospects, attributable to a highly engineered technology, reliable global distribution, a high share in niche markets, long and close working histories with customers, few competitors and solid product quality supplemented by technical service.
 
The company is considered to be the largest player in the filtration/separation industry based on its revenues and approximately 7% market share. Management’s efforts of reducing overall square footage by 20% and head count by 10% are expected to deliver $40 million in annualized savings and drive expansion in margins.
 
In the long run, Pall will likely benefit from several secular trends such as global infrastructure growth, increasing demand for clean and potable water and continued steady growth in medical and pharmaceutical markets.
 
Changes in product mix and product pricing may affect Pall’s operating results, particularly with the expansion of the systems business. The company experiences significantly longer sales cycles in the systems business, with less predictable revenues and no certainty of future revenue streams from related consumable product offerings and services.
 
The company may not be able to achieve the savings anticipated from its cost reduction and margin improvement initiatives.
 
Pall Corporation manufactures and markets filtration, purification and separation products and integrated systems solutions worldwide. The company’s Life Sciences segment offers technologies that facilitate the process of drug discovery, development, and production used in laboratories, pharmaceutical and biotechnology industries and health care.
 
We currently have a Neutral recommendation on Pall Corporation.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
RPC INC RES 24.91 +8.35%
LITHIA MOTO… LAD 94.59 +4.60%
DELTA AIR L… DAL 39.15 +3.90%
FLAMEL TECH… FLML 14.51 +3.50%
SOUTHWEST A… LUV 28.87 +2.92%